Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Colorcon
Boehringer Ingelheim
Mallinckrodt
Merck

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,561,244

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,561,244
Title:Anti-neoplastic compositions comprising extracts of black cohosh
Abstract: A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination, and compositions of a synergistic combination of a cardiac glycoside and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be a taxane are also provided. The compositions may also be used in a method for modulating Na.sup.+K.sup.+ATPase activity. In addition, a method for inhibiting the progression or development of breast cancer in vivo by administering either actein or an extract of black cohosh comprising triterpene glycosides and optionally at least one other chemoprotective agent is provided.
Inventor(s): Einbond; Linda Saxe (Crestwood, NY)
Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY)
Application Number:13/374,496
Patent Claims:1. A method for treating a neoplasia in a human, comprising administering to the human an amount of actein effective to treat the neoplasia and an effective anti-neoplastic amount of at least one additional chemotherapeutic agent, wherein the at least one additional chemotherapeutic agent is selected from the group consisting of cisplatin, doxorubicin, 5-fluorouracil, herceptin, paclitaxel, and tamoxifen, wherein the amount of actein is about 0.2 .mu.g/ml to 20.0 .mu.g/ml; and wherein the amount of cisplatin is about 2 .mu.g/ml to 20 .mu.g/ml, the amount of doxorubicin is about 0.02 .mu.g/ml to 0.2 .mu.g/ml, the amount of 5-fluorouracil is about 0.002 .mu.g/ml to 0.2 .mu.g/ml, the amount of herceptin is about 0.8 .mu.g/ml to 32 .mu.g/ml, the amount of tamoxifen is about 2 .mu.g/ml to 50 .mu.g/ml, and the amount of paclitaxel is about 0.5 nM to 5 nM.

2. The method of claim 1, wherein the neoplasia is a carcinoma, a lymphocytic leukemia, a myeloid leukemia, a malignant lymphoma, a malignant melanoma, a myeloproliferative disease, a sarcoma, a brain tumor, a childhood tumor, or a mixed type of neoplasia.

3. The method of claim 2, wherein the carcinoma is a breast carcinoma or a colon carcinoma.

4. The method of claim 1, wherein the chemotherapeutic agent is paclitaxel, wherein the amount of actein is between about 0.5 .mu.g/ml to about 5 .mu.g/ml, and the amount of paclitaxel is between about 0.5 nM to about 5 nM.

5. The method of claim 1, wherein the chemotherapeutic agent is herceptin, wherein the amount of actein is between about 0.2 .mu.g/ml to about 2 .mu.g/ml, and the amount of herceptin is about 8 .mu.g/ml to 32 .mu.g/ml.

Details for Patent 9,561,244

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY) 2022-12-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Mallinckrodt
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.